Bio-Rad Laboratories (BIO) Jefferies Global Healthcare Conference summary

Guidance and outlook

• 2024 guidance remains unchanged, supported by positive commercial and financial indicators, with expectations for a ramp in the second half of the year.

• Midterm guidance for 2025 will be updated around the fourth quarter, reflecting evolving market conditions since the 2022 investor day.

• A more definitive full-year perspective will be available after Q2, allowing for adjustments if necessary.

Management and organizational changes

• Ongoing management transformation aims to accelerate sales growth and improve margins, with a focus on bringing in new perspectives.

• The COO search is progressing, targeting candidates with broad management skills, industry experience, and CEO potential.

Product innovation and market positioning

• The Continuum platform, an entry-level digital PCR product, is set to launch in Q4 and is expected to contribute meaningfully in 2025.

• The new platform may open new applications and could impact the qPCR market.

• Digital droplet PCR growth has slowed due to biopharma weakness, but a gradual recovery is anticipated next year.